1 / 54

Renal Cell Carcinoma: An Overview

Renal Cell Carcinoma: An Overview. Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Assistant Professor of Urology. Background. Renal Cell Carcinoma – 2% of all malignancies Heterogeneous disease: clear cell RCC papillary RCC chromophobe RCC oncocytoma

killough
Download Presentation

Renal Cell Carcinoma: An Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Renal Cell Carcinoma: An Overview Douglas S. Scherr, M.D. Clinical Director, Urologic Oncology Assistant Professor of Urology

  2. Background • Renal Cell Carcinoma – 2% of all malignancies • Heterogeneous disease: clear cell RCC papillary RCC chromophobe RCC oncocytoma angiomyolipoma unclassified RCC

  3. N = 1120 Conventional

  4. Background • Prognosis determined by stage, grade and histologic subtype, clinical presentation • 30% of all cases are metastatic (12 mos life expectancy) • 30% of “localized” cases relapse after surgery

  5. P1 P2 P3a P3b P3c P4 M+ N+

  6. Median Tumor Size by Year p < 0.01

  7. 1 v 2 p = 0.17 2 v 3 p < 0.001

  8. ONC v PAP/CHR p=0.06 PAP v CHR p=0.80 CLR v PAP/CHR p <0.001

  9. INC v LOC p < 0.001 LOC v SYS p < 0.001

  10. A Postoperative Prognostic Nomogram for RCC Instructions for Physician: Locate the patient’s symptoms (I=incidental, L=local, S=systemic) on the Symptoms axis. Draw a line straight upwards to the Points axis to determine how many points towards recurrence the patient receives for his symptoms. Repeat this process for the otheraxes, each time drawing straight upward to the Points axis. Sum the points achieved for each predictor and locate this sum on the TotalPoints axis. Draw a line straight down to find the patient’s probability of remaining recurrence free for 5 years assuming he or she does not die of another cause first. Instruction to Patient: “Mr. X, if we had 100 men or women exactly like you, we would expect between <predicted percentage from nomogram – 10%> and <predicted percentage + 10%> to remain free of their disease at 5 years following surgery, though recurrence after 5 years is still possible.”

  11. Genetic Findings in RCC Subtypes _____________________________________________________________________________________________________________________________________________________ Histological % Early Genetic/ Late Genetic/ Associated Subtype MSKCC Molecular Defects Molecular Defects Syndromes *Zambrano N., Histopathology and Molecular Genetics of Renal Tumors J. Urol, Oct 1999

  12. Renal Cortical Tumors:Determination of Histological Subtype _____________________________________________________________________________________________________________________________________________________ • CT, MRI, and Ultrasound are non-specific. • Percutaneous or open tumor biopsy currently inaccurate in 40% of cases. • Possible effects of preoperative knowledge of histologic subtype on surgical management: • Extend indications for kidney-sparing surgery • Allow expectant management of small tumors • Inspire use of non-surgical alternative therapies

  13. Mortality and Cancer • Kidney cancer mortality has increased in spite of earlier detection of smaller renal masses • Prostate cancer has noted a 6.7% decrease in mortality in the last decade • Age adjusted mortality has risen in kidney cancer (SEER Data) 1975 – 3/100,0001995 – 3.5/100,000 **Rate of distant disease has steadily increased as well

  14. The Kidney Cancer Paradox Stage Migration >Rise in advanced disease + Early intervention=decline in mortality Re-evaluate aggressive surgical treatment of all small renal lesions Do tumors metastasize early, prior to intervention Do biologic markers exist to predict the propensity to metastasize early?

  15. Histology • Historically, only 40% accuracy rate • Modern series have been more accurate in interpretation of renal biopsies, but not necessarily in histology

  16. Immunohisotochemistry • Conventional (clear) cell RCC G-250, vimentin • Papillary RCC: c-met proto-oncogene • Chromophobe RCC: Hale’s colloidal iron, anti-mitochondrial antibody (113-1), parvalbumin • Oncocytoma: parvalbumin • Collecting Duct Carcinoma: CEA, PNA, UEA, Cytokeratins (34BE12 and CK7)

  17. Cytogenetics • Clear Cell RCC: 3p deletion (VHL) , LOH distal portion 3p, gain 5q, loss 9p/14q, p53 mutation, c-erB-1 expression • Papillary RCC: trisomy 7, 16, 17, loss of chromosome Y, translocation of X and 1, gain 12,16,20, loss 14,17,21, PRCC-TFE3 gene fusion protein • Chromophobe RCC: Loss 1 and Y, combined chromosomal losses of 1,6,10,13,17,21, hyperdiploid tumor cells, p53 mutation • Oncocytoma: Loss of chromosome 1 and Y most common, chromosome 9/11 and 5/11 translocations, c-erB-1 expression • Collecting Duct Carcinoma: monosomy of chromosomes 1,6,14,15,22, LOH of chromosomal arm 1q

  18. Molecular/Genetic Profiling • Need 1ug RNA: is core biopsy enough tissue for cDNA array analysis. • Modern gene chips have 39,000 genes for analysis • Precedent exists to re-classify RCC by genetic profiles

  19. Molecular Profiling of RCC • Emory Univ. –Am J Path, Vol 158(5), May 2001, pp1639 Evaluated 4 clear cell, one chromophobe, 2 oncocytomas with cDNA microarrays Large scale gene-expression patterns were able to distinguish clear cell from chromophobe/oncocytoma Chromophobe/oncocytomas: overexpressed distal nephron genes and genes involved with oxidative phosphorylation Clear Cell RCC: underexpressed mitochondrial and distal nephron genes, overexpressed vimentin, class II MHC-related genes

  20. Molecular Profiling of RCC • 29 clear cell tumors studied • Distinction in genetic profiles of aggressive vs. non-aggessive forms of clear cell • 40 genes were able to make distinction • Breast cancer example- BRCA1 and 2 – two genetically distinct forms Takahashi et al. PNAS 98(17): 9754-9759, 2001

  21. Goals of Molecular Profiling • Identify common alterations of varying histologic subtypes for diagnostic purposes • Identify expression signatures within each subgroup for staging/prognostic purposes (use normal kidney as internal control) – hierarchical clustering utilized to look at variation in gene expression • Correlate genetic profiles with outcome

  22. Proteomics • Can we utilize tissue/protein array to identify biomarkers for RCC • Collection of serum samples?

  23. Role of Nephrectomy in Metastatic Disease The Cytoreductive Nephrectomy

  24. CT Scan

  25. Ultrasound Guided Biopsy • Core biopsy: oncocytic renal neoplasm with focal papillary architecture, favor papillary renal cell carcinoma.

  26. MRI

  27. MRI

  28. Left Radical Nephrectomy • Embolization of 2 of 3 L renal arteries one day before surgery. • Left radical nephrectomy performed via thoracoabdominal approach • Significant hilar and retroperitoneal adenopathy was unresectable.

  29. Pathology(Left Kidney) CollectingductCa PapillaryCa

  30. Pathology Solid sheets; high nuclear grade

  31. Pathology(Retroperitoneal Mass) Metastatic Ca involving LN

  32. Pathology • Renal Cell Carcinoma, Unclassified • Tumor 15cm in greatest dimension • Extensive tumor necrosis • Extracapsular extension into perinephric fat • Renal vein free of tumor • Inked margins free of tumor • RP mass (5.5 cm) metastatic carcinoma involving lymph node c/w renal primary

  33. Postoperative Course • Doing well 3 months month postoperatively • Follow-up CT scan shows marked para-aortic, retro-aortic, retrocaval, and left common iliac LAD. • CT/CXR of the chest shows no evidence of disease • Enrolled in Atrogen and interferon clinical trial

  34. Case #2: History • 51 y.o. white male experiences new onset right sided focal seizures • PMHx/PSHx: RIH repair • No medications • Social Etoh; 15 pk/yr smoker, quit 24 yrs ago • FH: Both parents deceased due to MI (mother 80, father 61)

  35. Case #2 History – ER Evaluation • Nl exam, except R sided weakness • Laboratory: WNL • CT/MRI Head: 3 x 1.5 cm L hemispheric mass • CXR: R sided pulmonary nodules 3 x 1.5 cm • CT: confirms nodules, lower cuts show L renal mass 5-6 cm

  36. CT/ABD

  37. CT/ABD

  38. CT/ABD

  39. Management • Percutaneous Biopsy of renal lesion • Pathology consistent with renal cell carcinoma • Due to continuing seizures, patient undergoes L frontal craniotomy with sterotactic resection of tumor: RCC

  40. Case #2: Management • Recovers well from craniotomy; minimal R hand weakness; placed on dilantin • Undergoes L laproscopic nephrx • Pathology: 9 cm Grade II clear cell RCC invading peri-renal fat: pT3aN0M1

  41. Case #2: Management • Recovering well • Awaits start of immunotherapy

  42. SWOG 8949 Nephrectomy Followed by Interferon a-2b Compared with Interferon a-2b Alone for Metastatic Renal-Cell Cancer 2001;345(23):1655-1659 Robert C. Flanigan, M.D., Sydney E. Salmon, M.D., Brent A. Blumenstein, Ph.D., Scott I. Bearman, M.D., Vivek Roy, M.D., Patrick C. McGrath, M.D., John R. Caton, Jr., M.D., Nikhil Munshi, M.D., and E. David Crawford, M.D.

  43. EORTC 30947 2001 Sep 22;358(9286):966-70 Radical nephrectomy plus IFN-a based immunotherapy compared with IFN-a alone in metastatic renal-cell carcinoma: a randomized trial Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.

  44. Similarities – SWOG/EORTC • General Study Design: • Surgery + adjuvant IFN-a2b v. IFN-a2b alone • Intention to treat • Randomized • Treatment • Continuous 3x/wk regimen while tolerable • Surgery • Radical resection of primary tumor

  45. Study Criteria: SWOG & ECOG • Histologic dx of RCC • Metastases extending beyond regional lymphatics • Measurable disease in unresectable area by standard nephrx • Primary RCC amenable to resection • WBC ≥ 4, Cr < 3, nl plts, nl LFT’s • Performance status 0 or 1 • no prior immunotherapy • Brain metastases ineligible

  46. EORTC 30947

  47. EORTC 30947 Comparison of response rates: 19% vs 12%, P=0·38.

  48. EORTC 30947

  49. SWOG 8949

More Related